Martin J. Hessner, PhD
Professor, Pediatrics (Endocrinology); Director, Max McGee Research Center for Juvenile Diabetes
- Pediatrics (Endocrinology)
BS, Carroll College, Waukesha, WI, 1985
Type 1 diabetes (T1D) is an autoimmune disease that targets the pancreatic beta-cell. It is among the most common chronic childhood illness. T1D is a complex disease, meaning that it involves both genetic determinants as well as environment factors. In recent decades T1D is being diagnosed at an earlier age with an increasing incidence in most developed countries. This points towards increasing environmental pressure. It is known that T1D pathogenesis involves the expansion of autoreactive T-cells and B-cells. It also involves alterations in innate immune activity that are poorly understood.
The study of T1D has many challenges. Relevant tissues, such as pancreas and pancreatic lymph nodes are inaccessible from living patients. Cells and immune mediators associated with T1D are dilute in the periphery and difficult to detect. Further, a focus on one or a few mediators may be uninformative due to important combinatorial effects. To circumvent these obstacles, we have optimized a bioassay where patient plasma is co-cultured with a well-controlled ‘reporter’ cell population. The induced transcriptional signature is then globally measured with a microarray or through RNAseq, subjected to ontological analyses, and used to direct follow-up studies. This noninvasive approach enables an integrated functional assessment of the many plasma components (cytokines, chemokines, metabolites, microbial antigens). It allows for the sensitive detection and differentiation of immune states. This has fostered new insight in our studies of T1D.
Our laboratory uses the BioBreeding (BB) rat model of T1D. In the BB rat we have identified an underlying, partially interleukin-1 (IL-1) dependent, inflammatory state that is associated with T1D susceptibility, yet is independent of T1D progression. This state includes elevated plasma chemokine levels and beta-cell phenotypes consistent with microbial antigen exposure and pattern recognition receptor activation. BB DR (diabetes resistant) rats do not develop spontaneous diabetes; however, T1D can be triggered in young rats T1D by viral infection. Notably, we have discovered that the innate state in DR rats is temporally supplanted by an age-dependent IL-10/TGF-β-mediated regulatory state that coincides with the inability of virus to trigger T1D in older rats.
Similarly, our studies of diabetes patients, their healthy siblings and unrelated controls have also identified an innate inflammatory state in T1D families. This state is also consistent with pattern recognition receptor activation and includes elevated plasma cytokine levels, yet is independent of the high-risk HLA genotypes, autoantibody status, and T1D progression. Notably, among sibling non-progressors, the innate state is temporally supplanted by an IL-10/TGF-β-mediated regulatory state that includes increases in peripheral activated regulatory T-cell (Treg) frequencies. Our studies suggest that subclinical T1D progression is promoted when the underlying innate state is augmented by additional inflammatory signals (e.g. viral infection) prior to the establishment of protective regulatory mechanisms (Figure 1). This provides possible insight as to why T1D often develops in children and adolescents.
Our latest studies find that a higher innate inflammatory bias at T1D onset is predictive of 1) an accelerated rate of decline in post-onset β-cell function in newly diagnosed patients, and 2) greater responsiveness to immunotherapy at clinical onset. Since retention of even modest levels of β-cell function reduces the risk for microvascular complications and hypoglycemic events, gaining an understanding the variables that govern T1D progression is significant.
The rise in T1D incidence coincides with environmental changes that have likely altered the gut microbiota. These changes include increased antibiotic usage and introduction of the Western diet. Further, dysbiosis and intestinal hyper-permeability have been associated with T1D in rodent models and humans. Notably, we find that prebiotic and probiotic approaches that alter the composition of the GI microbiota can partially normalize the innate inflammatory state in BB rats and prevent T1D progression. We have also determined that probiotic supplement can partially normalize the familial inflammatory state in siblings of T1D patients.
Based on these observations, the Hessner Laboratory has two major ongoing initiatives:
The first area of focus is characterization of the immunological basis of the familial inflammation associated with T1D susceptibility, how levels of innate inflammation impact the rate of disease progression, and how variation in inflammation among new onset patients impacts the response to immunotherapy.
The second area of focus is how environmental factors, such as probiotics, may be leveraged to promote immunoregulation and possibly slow T1D progression before and at T1D onset.
Our long-term goal is to foster the development of disease modifying strategies in those with or at high risk of developing T1D, either using probiotics alone or in combination with other therapeutic agents.
Innate immune activity as a predictor of persistent insulin secretion and association with responsiveness to CTLA4-Ig treatment in recent-onset type 1 diabetes. (Cabrera SM, Engle S, Kaldunski M, Jia S, Geoffrey R, Simpson P, Szabo A, Speake C, Greenbaum CJ, Type 1 Diabetes TrialNet CTLA4-Ig (Abatacept) Study Group, Chen YG, Hessner MJ.) Diabetologia. 2018 11;61(11):2356-2370.
Modulation of the diet and gastrointestinal microbiota normalizes systemic inflammation and β-cell chemokine expression associated with autoimmune diabetes susceptibility. (Henschel AM, Cabrera SM, Kaldunski ML, Jia S, Geoffrey R, Roethle MF, Lam V, Chen YG, Wang X, Salzman NH, Hessner MJ.) PLoS One. 2018;13(1):e0190351.
Blood-based signatures in type 1 diabetes. (Cabrera SM, Chen YG, Hagopian WA, Hessner MJ.) Diabetologia. 2016 Mar;59(3):414-25.
Interleukin-1 antagonism moderates the inflammatory state associated with Type 1 diabetes during clinical trials conducted at disease onset. (Cabrera SM, Wang X, Chen YG, Jia S, Kaldunski ML, Greenbaum CJ, Type 1 Diabetes TrialNet Canakinumab Study Group, Mandrup-Poulsen T, AIDA Study Group, Hessner MJ.) Eur J Immunol. 2016 Apr;46(4):1030-46.
Innate inflammation in type 1 diabetes. (Cabrera SM, Henschel AM, Hessner MJ.) Transl Res. 2016 Jan;167(1):214-27. Molecular signatures differentiate immune states in type 1 diabetic families. (Chen YG, Cabrera SM, Jia S, Kaldunski ML, Kramer J, Cheong S, Geoffrey R, Roethle MF, Woodliff JE, Greenbaum CJ, Wang X, Hessner MJ.) Diabetes. 2014 Nov;63(11):3960-73.
(Hessner MJ, Cabrera SM.) J Clin Endocrinol Metab. 2020 Dec 01;105(12) PMID: 32542394 PMCID: PMC7531905 SCOPUS ID: 2-s2.0-85092680700 06/17/2020
(Nelson AJ, Stephenson DJ, Bone RN, Cardona CL, Park MA, Tusing YG, Lei X, Kokotos G, Graves CL, Mathews CE, Kramer J, Hessner MJ, Chalfant CE, Ramanadham S.) JCI Insight. 2020 Aug 20;5(16) PMID: 32814707 PMCID: PMC7455134 SCOPUS ID: 2-s2.0-85089714319 08/21/2020
(Raskin A, Borsheim K, Kim M, Brickler M, Jarzembowski J, Punnoose A, Chin C, Kindel S, Hessner M.) J Heart Lung Transplant. 2020 Apr;39(4S):S222 PMID: 32465119 SCOPUS ID: 2-s2.0-85085589451 05/30/2020
(Battaglia M, Ahmed S, Anderson MS, Atkinson MA, Becker D, Bingley PJ, Bosi E, Brusko TM, DiMeglio LA, Evans-Molina C, Gitelman SE, Greenbaum CJ, Gottlieb PA, Herold KC, Hessner MJ, Knip M, Jacobsen L, Krischer JP, Long SA, Lundgren M, McKinney EF, Morgan NG, Oram RA, Pastinen T, Peters MC, Petrelli A, Qian X, Redondo MJ, Roep BO, Schatz D, Skibinski D, Peakman M.) Diabetes Care. 2020 01;43(1):5-12 PMID: 31753960 PMCID: PMC6925574 SCOPUS ID: 2-s2.0-85077016324 11/23/2019
(Speake C, Skinner SO, Berel D, Whalen E, Dufort MJ, Young WC, Odegard JM, Pesenacker AM, Gorus FK, James EA, Levings MK, Linsley PS, Akirav EM, Pugliese A, Hessner MJ, Nepom GT, Gottardo R, Long SA.) JCI Insight. 2019 12 05;4(23) PMID: 31671072 PMCID: PMC6962023 11/02/2019
(Zhang X, Pan A, Jia S, Ideozu JE, Woods K, Murkowski K, Hessner MJ, Simpson PM, Levy H.) Am J Respir Cell Mol Biol. 2019 09;61(3):301-311 PMID: 30848661 PMCID: PMC6839930 SCOPUS ID: 2-s2.0-85071755620 03/09/2019
(Tsai S, McOlash L, Jia S, Zhang J, Simpson P, Kaldunski ML, Aldakkak M, Grewal J, Palen K, Dwinell MB, Johnson BD, Mackinnon A, Hessner MJ, Gershan JA.) Cancer Epidemiol Biomarkers Prev. 2019 04;28(4):680-689 PMID: 30530849 PMCID: PMC6545232 SCOPUS ID: 2-s2.0-85063867816 12/12/2018
(Levy H, Jia S, Pan A, Zhang X, Kaldunski M, Nugent ML, Reske M, Feliciano RA, Quintero D, Renda MM, Woods KJ, Murkowski K, Johnson K, Verbsky J, Dasu T, Ideozu JE, McColley S, Quasney MW, Dahmer MK, Avner E, Farrell PM, Cannon CL, Jacob H, Simpson PM, Hessner MJ.) Physiol Genomics. 2019 01 01;51(1):27-41 PMID: 30540547 PMCID: PMC6383551 SCOPUS ID: 2-s2.0-85060056850 12/13/2018
(Cabrera SM, Engle S, Kaldunski M, Jia S, Geoffrey R, Simpson P, Szabo A, Speake C, Greenbaum CJ, Type 1 Diabetes TrialNet CTLA4-Ig (Abatacept) Study Group, Chen YG, Hessner MJ.) Diabetologia. 2018 11;61(11):2356-2370 PMID: 30167736 PMCID: PMC6182660 SCOPUS ID: 2-s2.0-85052798832 09/01/2018
(Redondo MJ, Geyer S, Steck AK, Sharp S, Wentworth JM, Weedon MN, Antinozzi P, Sosenko J, Atkinson M, Pugliese A, Oram RA, Type 1 Diabetes TrialNet Study Group.) Diabetes Care. 2018 09;41(9):1887-1894 PMID: 30002199 PMCID: PMC6105323 07/14/2018
(Palatnik A, Ye S, Kendziorski C, Iden M, Zigman JS, Hessner MJ, Rader JS.) PLoS One. 2018;13(2):e0193687 PMID: 29474459 PMCID: PMC5825151 02/24/2018
(Henschel AM, Cabrera SM, Kaldunski ML, Jia S, Geoffrey R, Roethle MF, Lam V, Chen YG, Wang X, Salzman NH, Hessner MJ.) PLoS One. 2018;13(1):e0190351 PMID: 29293587 PMCID: PMC5749787 SCOPUS ID: 2-s2.0-85039965631 01/03/2018